收藏产品 产品信息
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The Human GIPR (Luc) HEK293 Reporter Cell was engineered to not only express CREB signaling response element, but also express the receptor full length human GIPR (Gene ID: 2696), which can drive luciferase expressing systems by GIPR agonists or Glucose-dependent insulinotropic polypeptide (GIP) stimulation. In the absence of agonist or GIP, the GIPR receptor is not activated and luminescence signal is low. In the presence of agonist or GIP, the GIPR pathway-activated luminescence can be detected in a dose-dependent manner.
应用说明（Application）
• Screen for agonists that can bind and activate GIPR.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL) + Hygromycin (20 μg/mL)
培养基（Complete Growth Medium）
DMEM medium + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
产品数据图
Receptor Assay
Expression analysis of human GIPR on Human GIPR (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human GIPR (Luc) HEK293 Reporter Cell or negative control cell using Alexa Fluor® 647-labeled anti-human GIPR antibody.
Protocol
Application
Bioactivity analysis of human GIPR agonist (RLU).
This reporter cell was incubated with serial dilutions of Tirzepatide (a dual GIPR and GLP-1R agonist). The EC50 of Tirzepatide was approximately 0.090 nM.
Protocol
Bioactivity analysis of human GIPR agonist (FOLD).
This reporter cell was incubated with serial dilutions of Tirzepatide (a dual GIPR and GLP-1R agonist). The max induction fold was approximately 75.22.
Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing Human GIPR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of Tirzepatide (a dual GIPR and GLP-1R agonist). Tirzepatide stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 5-22.
Protocol
产品评论 发表评论
背景
This gene encodes a G-protein coupled receptor for gastric inhibitory polypeptide (GIP), which was originally identified as an activity in gut extracts that inhibited gastric acid secretion and gastrin release, but subsequently was demonstrated to stimulate insulin release in the presence of elevated glucose. Mice lacking this gene exhibit higher blood glucose levels with impaired initial insulin response after oral glucose load. Defect in this gene thus may contribute to the pathogenesis of diabetes. [provided by RefSeq, Oct 2011]
数据表和文档 
联系我们 
项目合作